PHASE 2 INTERIM RESULTS: BRII-179 (VBI-2601), A PROTEIN-BASED HBV THERAPEUTIC VACCINE, INDUCED ROBUST HBSAB RESPONSES THAT ARE STRONGLY ASSOCIATED WITH INCREASED HBsAg LOSS IN SUBJECTS RECEIVING PEG-IFNα TREATMENT
机构:[1]Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China中山大学附属第三医院[2]Sichuan Univ, West China Hosp, Chengdu, Peoples R China四川大学华西医院[3]Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China[4]Publ Hlth Clin Ctr Chengdu, Chengdu, Peoples R China[5]Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China[6]First Peoples Hosp Yunnan Prov, Kunming, Peoples R China云南省第一人民医院[7]Sir Run Run Shaw Hosp, Hangzhou, Peoples R China[8]Brii Biosci Ltd, Beijing, Peoples R China[9]Brii Biosci Ltd, Rockville, MD USA